<DOC>
	<DOCNO>NCT01835613</DOCNO>
	<brief_summary>The purpose study assess clinical response IL-6 inhibition define Low Disease Activity ( DAS44 ) &lt; 2.4 ) follow-up visit 12 month correlation biomarkers treatment response .</brief_summary>
	<brief_title>Evaluation Effects Treatment With IL-6R Inhibitor Clinical Response Biomarkers Patients With Rheumatoid Arthritis ( RA ) Not Responding DMARDs and/or First Biological Agent .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent form ; Patients age 18 75 year ; RA classify compliance 2010 ACR/EULAR criterion ; Patients suspend previous treatment DMARDs total ineffectiveness intolerance drug and/or patient respond adequately firstline combination DMARDs / biological treatment ; Patients indicate start treatment inhibitor IL6R high value indicative systemic inflammation ( ESR &gt; =28 mm/hour , PCR &gt; 5 mg/l , Fibrinogen &gt; 400 mg/dl Albumin &lt; 3.5 g/dl ) high disease activity ( DAS &gt; 2.4 ) , contraindication DMARDs use make necessary take biological drug monotherapy . Corticosteroids therapy stable ( &lt; = 7.5 mg ) least four week ; Joint symptom least three 24 month screen visit ; DAS44 &gt; 2.4 and/or SDAI &gt; 11 Willing able comply study procedure time . Exclusion criterion : On go pregnancy lactation ; Severe active infection ; Patients clinically significant concomitant disease whose treatment outcome could interfere expect evaluation study protocol . Blood AST ALT level &gt; 5 time upper normal limit ; ANC count &lt; 0.5 x 109/L Platelet count &lt; 50 x103 /μL Patients autoimmune rheumatic disease , addition AR ( example systemic lupus erythematosus [ SLE ] , scleroderma , polymyositis , ecc… ) Medical history concomitant joint disease addition AR ( example tophaceous gout , reactive arthritis , psoriatic arthritis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Early RA</keyword>
	<keyword>RA</keyword>
	<keyword>IL-6</keyword>
	<keyword>IL-6R</keyword>
	<keyword>Inhibitor</keyword>
	<keyword>Inhibition</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>DMARDs</keyword>
	<keyword>Biological</keyword>
	<keyword>DAS</keyword>
	<keyword>SDAI</keyword>
	<keyword>AR/BIOM</keyword>
	<keyword>OEG</keyword>
</DOC>